nod1

NOD1 2 Antagonist-1 is a potent dual inhibitor of nucleotide-binding oligomerization domain-like receptors 1 and 2 (NOD1 2), displaying inhibitory concentrations (IC50) of 1.13 μM for NOD1 and 0.77 μM for NOD2. It exhibits an acceptable half-life (T1 2) of 67.6 minutes. Additionally, NOD1 2 Antagonist-1 enhances the antitumor efficiency of Paclitaxel (PTX).

NOD1 2-IN-1 (Compound 2) is a potent inhibitor of RIPK2 with an IC50 value of 0.65 nM as determined by the ADP-Glo assay. It selectively inhibits the NOD1 pathway, with an IC50 of 33 nM, effectively blocking the production of pro-inflammatory cytokines and thereby reducing inflammatory responses. This compound has potential applications in the research of colitis.

NOD1 2-IN-1 (Compound 18) is a potent RIPK2 inhibitor, demonstrating an IC50 value of 1.4 nM in the ADP-Glo assay. It blocks the production of pro-inflammatory cytokines by inhibiting the NOD1 NOD2 pathway (IC50 values are 18 nM and 170 nM for NOD1 and NOD2, respectively), thereby reducing inflammatory responses. This compound is utilized in research related to colitis.

NOD1antagonist-2 (compound 66) is an orally active and selective inhibitor that can suppress NOD1 in both humans and mice. It effectively blocks the NOD1-induced NF-κB and MAPK pathways.

NOD1-RIPK2-IN-1 (Compound 37) is an inhibitor of the NOD1-RIPK2 signaling pathway, displaying potent IC50 values of 42 nM and 1.52 nM against NOD1 and RIPK2, respectively. This compound effectively reduces the secretion of the pro-inflammatory cytokine IL-8, making it valuable for research in inflammation and immune disorders.

Nodinitib-1 (CID-1088438) is a potent and selective NOD1 inhibitor with an IC50 of 0.56 μM.

TriDAP (L-Ala-γ-D-Glu-meso-diaminopimelic acid), a biologically active peptide, functions as a specific Nod1 activator.

FK-565 is a ligand of nucleotide-binding oligomerization domain-1 (NOD1) that induces a mouse model of arteritis.

NOD-IN-1 (Compound 4) is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors.

7,4'-Dihydroxyflavone (4',7-Dihydroxyflavone) can induce transcription of nodulation (nod) genes in Rhizobium meliloti. It has inhibitory activities against COX-2.

GSK223 is an iE-DAP-stimulated IL-8 release inhibitor via the NOD1 signaling pathway.

iE-DAP is a biologically active peptide that functions as a NOD1 agonist.

M-TriDAP (N-Acetylmuramyl-L-Ala-γ-D-Glu-meso-diaminopimelic acid) is a bioactive peptide that functions as a NOD1 2 agonist.

CSLP37 is a selective RIPK2 inhibitor with an IC50 of 16.3 nM and demonstrates no inhibitory activity against RIPK1 or RIPK3. Additionally, CSLP37 effectively suppresses cellular responses mediated by NOD1 and NOD2.

C12-iE-DAP (Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid) is a biologically active peptide featuring a lauroyl (C12) group bonded to the glutamate residue of iE-DAP, an agonist of NOD1.

RIPK2 3-IN-1 is a potent inhibitor of both RIPK2 and RIPK3 kinases, exhibiting IC50 values of 3 nM for RIPK2 and 117 nM for RIPK3. Additionally, in a 14-TriLAN-Gly NOD1 THP-1 cell-based NF-κB reporter assay, RIPK2 3-IN-1 demonstrates an IC50 value of 14 ± 4 nM against RIPK2 [1].

GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor that inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293 hNOD2 cells[1]. It blocks the synergy between NOD2 and TLR2 without affecting NOD1, TNFR1, and TLR2-mediated responses. At 5 μM, GSK717 inhibits the release of IL-8, IL-6, TNFα, and IL-1β in primary human monocytes stimulated with MDP[1]. [1]. Rickard DJ, et al. Identification of benzimidazole diamides as selective inhibitors of the nucleotide-binding oligomerization domain 2 (NOD2) signaling pathway. PLoS One. 2013;8(8):e69619. Published 2013 Aug 1.